Treatment Recommendations for Pulmonary Hypertension Groups
Endothelin receptor antagonists (ERAs) are NOT appropriate for all pulmonary hypertension groups—they are specifically indicated only for Group 1 (pulmonary arterial hypertension) and should NOT be used routinely in Groups 2,3, or 5. 1, 2
Group-Specific Treatment Approach
Group 1: Pulmonary Arterial Hypertension (PAH)
ERAs are a cornerstone therapy for Group 1 PAH. The treatment strategy is risk-stratified:
Low/Intermediate Risk Patients (WHO FC II-III):
- Initial oral combination therapy with a PDE5 inhibitor plus an ERA is recommended (e.g., tadalafil + ambrisentan) 3
- This combination has proven superior to monotherapy in delaying clinical failure 3
- Alternative: Initial monotherapy with ERA (bosentan, ambrisentan, or macitentan) followed by sequential combination if inadequate response 1, 4
High Risk Patients (WHO FC IV):
- Initial triple combination therapy including intravenous prostacyclin analogues (preferably IV epoprostenol) plus ERA plus PDE5i should be considered 3
- IV epoprostenol should be prioritized as it has reduced 3-month mortality in high-risk PAH patients 3
Sequential Escalation:
- If inadequate clinical response to initial therapy, escalate to double or triple sequential combination therapy 3
- Consider lung transplantation referral after inadequate response to maximal combination therapy 3
Group 2: PH Due to Left Heart Disease
ERAs and other PAH-specific drugs are NOT recommended 1
Treatment focuses on:
- Optimal management of the underlying left heart disease (Class I recommendation) 1
- Patients with "out of proportion" PH should be enrolled in randomized controlled trials targeting PH-specific drugs, but routine use outside trials is contraindicated 1
Critical Pitfall: Using PAH-specific therapies in Group 2 may cause harm and has not demonstrated benefit 2
Group 3: PH Due to Lung Diseases and/or Hypoxemia
ERAs and other PAH-specific drugs are NOT recommended 1, 2
Treatment consists of:
- Optimal treatment of the underlying lung disease (Class I recommendation) 1
- Long-term oxygen therapy in patients with chronic hypoxemia 1
- Patients with "out of proportion" PH should be enrolled in RCTs, but routine PAH-specific therapy is contraindicated 1
Group 4: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Surgical pulmonary endarterectomy is the recommended first-line treatment (Class I) 1
ERAs may be indicated in selected circumstances:
- Patients not candidates for surgery 1
- Patients with residual PH after pulmonary endarterectomy 1
- Lifelong anticoagulation is mandatory for all CTEPH patients 1
Group 5: PH with Unclear/Multifactorial Mechanisms
PAH-specific drugs including ERAs are NOT routinely recommended 5
Treatment focuses on:
- Management of the underlying causal disease 5
- Referral to PH centers for potential study inclusion or individualized therapy in severe cases (PVR >5 Wood units) 6
Key Mechanistic Distinctions
The restriction of ERAs to Group 1 PAH is based on pathophysiology:
- Group 1 PAH involves endothelin-1-mediated vasoconstriction and vascular remodeling of small pulmonary arteries (<500 μm), making ERA therapy mechanistically appropriate 4, 5
- Groups 2 and 3 have different underlying mechanisms (left heart disease, lung parenchymal disease) where blocking endothelin receptors does not address the primary pathology and may worsen outcomes 2
- Group 4 is primarily a mechanical obstruction requiring surgical intervention 1
Safety Considerations
All ERAs (bosentan, ambrisentan, macitentan):
- Can cause fetal harm and are contraindicated in pregnancy 7
- Require monitoring for hepatotoxicity (particularly bosentan) 4
- Should not be combined with riociguat and PDE5i simultaneously (contraindicated combination) 3
The evidence strongly supports that attempting to use ERAs outside Group 1 PAH (except selected Group 4 cases) exposes patients to cost, side effects, and potential harm without demonstrated benefit. 2